KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Cost of Revenue (2018 - 2026)

Alnylam Pharmaceuticals filings provide 9 years of Cost of Revenue readings, the most recent being $207.5 million for Q1 2026.

  • Quarterly Cost of Revenue rose 195.68% to $207.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $814.5 million through Mar 2026, up 152.89% year-over-year, with the annual reading at $677.2 million for FY2025, 120.93% up from the prior year.
  • Cost of Revenue hit $207.5 million in Q1 2026 for Alnylam Pharmaceuticals, down from $267.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $267.7 million in Q4 2025 and bottomed at $23.5 million in Q1 2022.
  • Average Cost of Revenue over 5 years is $94.1 million, with a median of $72.0 million recorded in 2023.
  • The largest annual shift saw Cost of Revenue dropped 10.71% in 2024 before it skyrocketed 195.68% in 2026.
  • Alnylam Pharmaceuticals' Cost of Revenue stood at $46.2 million in 2022, then soared by 55.88% to $72.0 million in 2023, then skyrocketed by 42.62% to $102.6 million in 2024, then surged by 160.81% to $267.7 million in 2025, then dropped by 22.49% to $207.5 million in 2026.
  • Per Business Quant, the three most recent readings for ALNY's Cost of Revenue are $207.5 million (Q1 2026), $267.7 million (Q4 2025), and $197.2 million (Q3 2025).